---
schema_version: "secwatch.filing_event.v1"
accession: "0001178670-26-000060"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2026-07-30T12:06:25+00:00"
generated_at: "2026-07-30T12:10:10.720515+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alnylam Q2 product rev $1.17B (+74% YoY); cuts FY TTR guidance to $4.2-4.5B

## Summary
- Q2 2026 net product revenues $1,172M (+74% YoY); TTR franchise $1,030M (+89% YoY).
- GAAP net income $164.5M ($1.23 diluted EPS) vs loss of $72.2M in Q2 2025.
- Full-year 2026 TTR revenue guidance revised down to $4.2-4.5B from $4.4-4.7B (75% growth at midpoint).
- Rare disease revenues $142M (+11% YoY) from GIVLAARI and OXLUMO.
- Initiated Phase 2 trials for ALN-6400 (von Willebrand) and mivelsiran (Down syndrome Alzheimer's).

## SEC filing metadata
- accession: 0001178670-26-000060
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2026-07-30T12:06:25+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000117867026000060/0001178670-26-000060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000117867026000060/alny-20260730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178670-26-000060
- JSON: https://secwatch.observer/filing/0001178670-26-000060.json
- Plain text: https://secwatch.observer/filing/0001178670-26-000060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.